奥扎格雷钠联合阿加曲班治疗短暂性脑缺血发作的疗效观察

Clinical efficacy of sodium ozagrel combined with argatroban to treat transient ischemic attack

目的:观察奥扎格雷钠联合阿加曲班治疗短暂性脑缺血发作(TIA)的疗效。方法:2011年1月—2012年12月在某院就诊的脑缺血发作患者230例随机分为观察组和对照组,每组各115例。2组患者均接受常规治疗,对照组在常规治疗基础上静脉滴注用奥扎格雷钠,观察组患者在常规治疗基础上静脉滴注用奥扎格雷钠和微量泵输注阿加曲班。治疗前及治疗后进行血液流变学测定、脑血管血流动力学和血小板活性测定,并比较2组患者的临床治疗效果。结果:治疗后2组患者血液流变学、脑血管血流动力学和血小板活性均显著改善(P<0.01),并且观察组改善优于对照组(P<0.01);观察组患者TIA发作平均停止时间为(44.32±16.43)h,显著低于对照组(P<0.01);治疗后1个月内观察组有1例(0.87%)患者出现脑梗死,显著低于对照组(P<0.01)。结论:奥扎格雷钠联合阿加曲班治疗短暂性脑缺血发作有显著疗效,并且可以改善患者的血液流变学、脑血管血流动力学和血小板活性。

OBJECTIVE To observe the clinical efficacy of sodium ozagrel combined with argatroban to treat transient ische- mic attack （TIA）. METHODS 230 patients with TIA,who visited our hospital from Jan. 2011 to Dec. 2012,were divided into observation group and control group. There were 115 eases in each group. Cases in both groups received basic treatment. Cases in control group received sodium ozagrel by intravenous infusion,and cases in observation group received sodium ozagrel by in-travenous infusion and argatroban by micro pump. The indicators of hemorheology, cerebravascular haemodynamics and platelet activity were determined before and after treatment,and the clinical efficacy of both groups was compared. RESULTS The indi- cators of hemorheology, cerebravascular haemodynamics and platelet activity were significantly improved after treatment （P〈0.01 ） in both groups, and the improvement of the above-mentioned indicators in observation group was better than that in con- trol group （P〈0. 01）. The average offtime of TIA in observation group was （44. 32±16. 43） h,which was significantly short- ened compared with that in control group. There was 1 case （0. 87%） suffering with TIA in one month after treatment,which was significantly less than those in control group （P〈0. 01 ）. CONCLUSION Sodium ozagrel Combined with argatroban has a favorable efficacy to treat TIA, and can significantly improve hemorheology, cerebravascular haemodynamics and platelet activity of patients with TAI.